
AngioDynamics, Inc. ANGO will release earnings results for its first quarter, before the opening bell on Thursday, Oct. 3.
Analysts expect the Latham, New York-based company to report a quarterly loss at 15 cents per share, versus a year-ago loss of 12 cents per share. AngioDynamics is projected to post quarterly revenue of $67.93 million, according to data from Benzinga Pro.
On Sept. 3, AngioDynamics announced CE Mark approval for Auryon System in Europe.
AngioDynamics shares gained 0.3% to close at $7.65 on Wednesday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
Considering buying ANGO stock? Here’s what analysts think:

Read This Next:
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.